Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rosacea, Papulopustular Clear all
Completed Phase 1Phase 2 Interventional Results available

An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema

NCT01933464
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Cromolyn Sodium, Normal Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 1Phase 2 Interventional

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

NCT03050086
View directory record Official record
Conditions
Moderate to Severe Papulopustular Rosacea
Interventions
BPX-04 1% minocycline topical gel, BPX-04 2% minocycline topical gel, BPX-04 vehicle topical gel
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 1 Interventional

Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

NCT05675501
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Encapsulated Benzoyl Peroxide Cream
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jul 22, 2026, 8:17 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

NCT07681271
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
LOU064, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

NCT05343455
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Santa Monica, California • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

NCT02576860
View directory record Official record
Conditions
Rosacea
Interventions
CLS001 (Omiganan), Vehicle
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
20
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Manhattan Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 8:17 PM EDT
Withdrawn Phase 2 Interventional

Deucravacitinib Rosacea

NCT06532136
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Rosacea Treatment Using Non-thermal (Cold) Atmospheric Plasma Device

NCT05592548
View directory record Official record
Conditions
Rosacea, Papulopustular
Interventions
cold atmospheric plasma
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Genetic Basis of Rosacea Study (Control)

NCT02749786
View directory record Official record
Conditions
Rosacea
Interventions
Skin Biopsy
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated Phase 2 Interventional

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

NCT06013371
View directory record Official record
Conditions
Seborrheic Dermatitis, Papulopustular Rosacea
Interventions
PF-07038124, Placebo Ointment
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

NCT02268474
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Interventions
532nm KTP Laser vs 595nm Pulse Dye Laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
20 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 22, 2026, 8:17 PM EDT
Not listed Phase 2 Interventional

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

NCT03667222
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
minocycline topical gel, topical gel vehicle
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Anaheim Hills, California • Miami, Florida • Miramar, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Jul 22, 2026, 8:17 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Safety and Efficacy Study to Evaluate Rosacea

NCT03883945
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
AIV001, Vehicle
Drug
Lead sponsor
AiViva BioPharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

NCT03079531
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Secukinumab
Drug
Lead sponsor
Anne Chang
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Study of Ivermectin 1% Cream

NCT02840461
View directory record Official record
Conditions
Moderate to Severe Papulopustular Rosacea
Interventions
Ivermectin Cream, 1%, Placebo/Vehicle cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03276936
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
FMX103 1.5%
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
79
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Twelve Week Safety and Efficacy Study in Rosacea

NCT01784133
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
omiganan, placebo
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Santa Monica, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

NCT01257919
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic Acid Foam, Azelaic Acid Gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 2 Interventional

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

NCT00249782
View directory record Official record
Conditions
Rosacea
Interventions
Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Jul 22, 2026, 8:17 PM EDT
Terminated Phase 3 Interventional Results available

A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

NCT03564145
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
S5G4T-1
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Jul 22, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT03142451
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
54
States / cities
Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jul 22, 2026, 8:17 PM EDT